Disease modifying treatment

Interferon beta for secondary progressive multiple sclerosis

Abstract Background Therapy with either recombinant beta-1a or beta-1b interferons (IFNs) is worldwide approved for Relapsing Remitting Multiple Sclerosis (RRMS). A major unanswered question is whether this treatment is able to safely reverse or retard the progressive phase of the disease. Objectives The main objective was to verify whether IFNs treatment in Secondary Progressive Multiple […]

Share

Interferon Beta for Primary Progressive Multiple Sclerosis

Abstract Background This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006643. DOI: 10.1002/14651858.CD006643.pub2). Therapeutic trials with ß-interferon in Multiple Sclerosis (MS) have mainly focused on remitting-relapsing multiple sclerosis (RRMS), demonstrating a reduction in relapse rate. However, there is not enough evidence about […]

Share

Azathioprine for multiple sclerosis

Abstract Background Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS). It is an alternative to interferon beta for treating MS also because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, has limited its use. Objectives To compare azathioprine versus placebo. To determine the effect […]

Share

Interferon in relapsing-remitting multiple sclerosis

Abstract Background Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). Objectives The objective of this review was to assess the effects of recombinant interferons in adults with RRMS. Search methods We searched the Cochrane Multiple Sclerosis […]

Share

Intravenous immunoglobulins for multiple sclerosis

Abstract Background Animal experiments suggest that intravenous immunoglobulins can reverse some of the disease process of central nervous system demyelination. Subsequently, clinical trials of intravenous immunoglobulins have been conducted in people with multiple sclerosis (MS). Objectives To identify and summarise the evidence that intravenous immunoglobulins are safe and beneficial for people with MS. Search methods […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share